68 results about "High-Fat Diets" patented technology

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention provides application of quinoa seedling acidic polysaccharide or modified acidic polysaccharide thereof in preparation of drugs for improving lipid metabolism disorder or health-care food beneficial to maintaining the health level of blood fat. The invention further provides the quinoa seedling modified acidic polysaccharide and a preparation method thereof. According to the invention, the quinoa seedling acidic polysaccharide is subjected to structural modification, and by comparing the physical and chemical structural characteristics of the quinoa seedling acidic polysaccharide before and after modification and the health effect of improving lipid metabolism disorder, the quinoa seedling acidic polysaccharide and the modified acidic polysaccharide thereof are found to be capable of remarkably improving the lipid metabolism disorder of mice induced by high fat diet; particularly, the quinoa seedling modified acidic polysaccharide prepared by a directional enzyme digestion technology has the best effect. A scientific theoretical basis and a key processing technology are provided for research and development of functional / healthy quinoa seedling food, and nutritional and high-value utilization of quinoa seedlings is facilitated.

The invention provides a mulberry phellinus linteus strain SH08, mulberry phellinus linteus polysaccharide as well as a preparation method and application of the mulberry phellinus linteus polysaccharide, and belongs to the technical field of biological medicines and functional foods. The mulberry phellinus igniarius strain SH08 provided by the invention is preserved in the China Center for Type Culture Collection on October 11, 2025, the preservation address is No. 299, eight road, Wuchang District, Wuhan City, Hubei Province, the strain preservation number is CCTCC NO: M20252203, and the mulberry phellinus igniarius strain SH08 is named as SanghuangAKSQSH01. The invention also provides a method for preparing high-purity mulberry phellinus linteus polysaccharide (SHP-PS) from sporocarp of the strain, and structural characterization of the polysaccharide. Experiments prove that the SHP-PS can effectively improve non-alcoholic fatty liver disease (NAFLD) induced by high fat diet, and the mechanism of the SHP-PS is closely related to blood fat regulation, liver injury and inflammation reduction, intestinal barrier repair, intestinal flora structure regulation and short-chain fatty acid generation promotion. The invention provides high-quality raw materials and a clear technical scheme for developing novel medicines or functional foods for preventing and treating NAFLD, and has important application value.

The invention discloses a pediococcus pentosaceus MDL511, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 has the advantages that the preservation number is CGMCC No.35201, the preservation number is CGMCC No.35201, the preservation date is July 11, 2025, and the classification name of the strain is pediococcus pentosaceus. The pediococcus pentosaceus MDL511 disclosed by the invention can be used for remarkably reducing weight gain and fat growth of mice caused by high fat diet, reducing serum cholesterol, LDL-C (Low Density Lipoprotein Cholesterol) and ALT (Atomic Lymphocyte Transferase) levels and remarkably improving hepatic lesions and fat accumulation caused by high fat diet, so that the MDL511 has a blood fat reducing effect, can be used for preparing blood fat reducing products and weight losing products and has a good development prospect.

This invention discloses a functional Cistanche deserticola polysaccharide, its preparation method, and its applications. Using Cistanche deserticola as raw material, the polysaccharide is first extracted by cell wall disruption using an oxygen free radical-cellulase synergistic technology. The optimal extraction parameters are optimized through single-factor experimental design, overcoming the limitations of traditional methods and achieving efficient, green, and activity-preserving extraction of Cistanche deserticola polysaccharide, providing a high-quality material basis for subsequent research. The Cistanche deserticola polysaccharide extracted by this method can slow down weight gain in obese C57BL / 6J mice induced by a high-fat diet and improve glucose and lipid metabolism disorders. It also induces the production of important biomarkers such as indole, decanoic acid, and nonanoic acid by the intestinal flora of mice. This invention obtains Cistanche deserticola polysaccharides with specific biological activities, achieving high-quality utilization of Cistanche deserticola.

The present invention provides a composition for alleviating fatty liver disease by using a single or complex extract of Sigesbeckia glabrescens and Luffa cylindrica, the composition exhibiting the activities of inhibiting fat accumulation and inflammation in liver cells without showing toxicity to liver cells, inhibiting fat accumulation and inflammation in liver tissue in high-fat-diet animal models, and increasing the expression of glutathione, which is a strong antioxidant in liver tissue.

The invention discloses an application of probiotic metagen and organic acid in improvement of liver health and colitis, and relates to the technical field of metagen. The invention discovers that both malic acid and / or sebacic acid and acellular supernatant of K56 inactivated bacteria can significantly inhibit the expression of proinflammatory factors, and both have good anti-inflammatory activity. After intervention of K56 acellular supernatant, malic acid and sebacic acid, abnormal liver weight gain of a subject caused by high-fat diet can be relieved, and liver injury caused by the high-fat diet is relieved. Therefore, development of sebacic acid, malic acid or mixed organic acid of malic acid and sebacic acid has a good application prospect in preparation of products for improving liver health. In addition, after intervention of malic acid or sebacic acid, the basic phenotype of the DSS-induced colitis of the test body is relieved. The invention has a good application prospect for developing and preparing products for preventing or treating acute colitis or ulcerative colitis.

The application discloses a functional tea polysaccharide as well as a preparation method and application thereof. The tea polysaccharide is prepared by using coarse old tea leaves as raw materials, and the raw materials are pretreated by supermicronization and dewaxing and small molecule impurities, and then are extracted by adopting cellulase-papain compound wall breaking, and further treated by adopting hydrogen peroxide, so that the tea polysaccharide with high yield and strong biological activity is obtained. The tea polysaccharide extracted by the method can slow down the weight increase of obese C57BL / 6J mice caused by high-fat diet, improve glycolipid metabolism disorder, and make db / m mice intestinal flora metabolize to produce new functions of important biomarkers such as indole, so that the high-quality reuse of coarse old tea leaves is realized.

The invention belongs to the technical field of biological medicine, and provides a human umbilical cord mesenchymal stem cell preparation and application thereof, the preparation comprises human umbilical cord mesenchymal stem cells, ginsenoside Rg3 and a medicinal carrier; the medicinal carrier is a phosphate buffer solution; according to the application, 1 * 10 < 6 > HUCMSCs pretreated by Rg3 are subjected to caudal vein injection on a T2DM mouse model induced by high fat diet combined with STZ, the curative effect and mechanism are verified by combining OGTT, IPITT, serum biochemical detection, HE / PAS tissue staining, q-PCR and other technologies, and finally the purposes of improving glycometabolism of the T2DM mouse, repairing liver / kidney / pancreas target organ injuries, protecting pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions and the like are achieved. And a theoretical basis is provided for accurate intervention of T2DM by activating an IGF-1R / PI3K-AKT signal channel and regulating and controlling the expression of a glycometabolism-related gene.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The invention relates to the field of microorganisms, and discloses application of aspergillus cristatus in preparation of a medicine for preventing and / or treating hyperglycemia and / or hyperlipidemia, and the preservation number of the aspergillus cristatus is CGMCC No.41727. The aspergillus cristatus provided by the invention can degrade cholesterol, has the activity of degrading cholesterol and sugar-related enzymes, can relieve the symptoms of hyperlipidemia and hyperglycemia of high-fat diet mice, and has an application prospect in drugs for preventing and / or treating hyperglycemia and / or hyperlipidemia.

The invention discloses compound safflower tea capable of reducing blood lipid. The compound safflower tea consists of the following components: 0.19 to 0.21 g of safflower, 0.195 to 2.050 g of American ginseng, 0.90 to 1.10 g of green tea, 1.10 to 1.20 g of hawthorn and 1.35 to 1.45 g of lotus leaf. According to the present invention, the C57BL / 6J mouse is subjected to the lipid-lowering experiment by using the safflower as the main material and using the American ginseng, the green tea, the hawthorn and the lotus leaf as the auxiliary materials, and the result shows that the safflower lipid-lowering tea can significantly reduce the levels of serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C), can improve the liver fatty degeneration and the inflammatory reaction, and can alleviate the intestinal injury caused by the high fat diet; animal behavior experiments including Y maze, open field experiments and new object recognition experiments are used to verify that the safflower lipid-lowering tea has an improvement effect on mouse cognitive impairment caused by dyslipidemia.

The application discloses an application of lactobacillus reuteri BNCC186563 in prevention and improvement of related diseases caused by high-fat diet and belongs to the technical field of microorganisms. It is found that the lactobacillus reuteri BNCC186563 can synergistically activate a PPAR alpha signal pathway and remodel a glycerophospholipid metabolism network, and the lactobacillus reuteri BNCC186563 can be used as a potential medicine, health care product and functional food for preventing and improving related diseases caused by high-fat diet, such as obesity, impaired glucose tolerance, insulin resistance, abnormal lipid metabolism, liver lipid accumulation, liver damage, inflammation and hyperlipidemia.

The invention belongs to the technical field of biomedicine, and particularly relates to a method for detecting potential biomarkers of myocardial of an HFpEF mouse based on non-targeted metabonomics, which comprises the following steps: constructing an HFpEF mouse model by combining high fat diet with L-NAME, setting a conventional feeding control group, monitoring myocardial glucose metabolism through longitudinal [18F] FDG PET / CT, collecting myocardial tissues, and performing non-targeted metabonomics detection. And screening differential metabolites through Foldchange greater than or equal to 1.2 or less than or equal to 0.83 and p less than 0.05, and carrying out correlation analysis on the differential metabolites and [18F] FDG SUVmean to obtain 25 potential biomarkers. According to the method, the steps are clear and repeatable, the marker is directly related to myocardial energy metabolism, the diagnosis specificity is improved, and a support is provided for HFpEF targeted therapy research and development and molecular mechanism research.

The application discloses a liver-protecting EPA fish oil composition for high-fat-diet people and relates to the technical field of functional health foods and dietary supplements; the application takes high-purity EPA fish oil as a core active ingredient and adopts scientific proportioning and refining processes, so that the excellent effect of EPA in regulating liver lipid metabolism is ensured, and meanwhile, the composition of the application further adds natural active ingredients which have synergistic liver-protecting effects with EPA, so that a double-path liver-protecting system is formed, liver lipid metabolism is regulated, liver cell structure is repaired, oxygen free radicals are removed, and inflammatory reactions are inhibited, and thus, comprehensive protection of the liver is realized.

This invention belongs to the field of traditional Chinese medicine and discloses the application of total saponins extract of *Abrus precatorius* in the preparation of drugs for treating metabolic-associated fatty liver disease (MAFLD). Through experiments in high-fat diet-induced MAFLD mice, this invention demonstrates that total saponins of *Abrus precatorius* can protect the liver from a series of damages caused by excessive lipid accumulation. The potential mechanisms include regulating lipid metabolism through the PPAR and AMPK signaling pathways, and modulating the balance of gut microbiota. These findings provide a solid research foundation and empirical evidence for the potential application of total saponins of *Abrus precatorius* in the treatment of MAFLD.

This invention provides *Pediococcus lactis* SHI03 and its application in alleviating insulin resistance and type 2 diabetes, belonging to the field of microbial technology. This invention provides *Pediococcus lactis* SHI03, with accession number CCTCC No: M 20242686, and confirms that this strain possesses in vitro α-glucosidase inhibitory activity, exhibiting excellent probiotic and hypoglycemic effects. This invention further provides microbial products containing *Pediococcus lactis* SHI03, including *Pediococcus lactis* SHI03 fermentation broth, *Pediococcus lactis* SHI03 fermentation supernatant, and *Pediococcus lactis* SHI03 cells, and their applications in alleviating high-fat diet-induced insulin resistance and reducing fasting blood glucose in type 2 diabetic mice.

The invention relates to application of procyanidine B2 in preparation of a product for delaying or treating senescence induced by high fat diet, and relates to the technical field of biological medicine. Long-term animal experiments prove that long-term supplement of procyanidine B2 can significantly prolong the life of high-fat diet mice, regulate intestinal flora and comprehensively improve healthy life indexes such as cognition, athletic ability and body weakness states, a foundation is laid for research and development of products for treating senescence induced by high-fat diet, and the procyanidine B2 has a broad application prospect in treatment of senescence induced by high-fat diet. Good application and popularization prospects are realized.

The invention discloses application of indoleacetic acid in diagnosis and treatment of gestational diabetes mellitus. Clinical queue research finds that the concentration of serum indoleacetic acid of pregnant women in a gestational diabetes mellitus group is remarkably lower than that of pregnant women in a healthy control group, and high diagnosis efficiency is achieved. Animal experiments further prove that in a high fat diet induced mouse model with gestational diabetes mellitus, the exogenous indoleacetic acid is supplemented, so that the fasting blood glucose of a female mouse with gestational diabetes mellitus can be reduced, abnormal glucose tolerance and insulin resistance can be improved, and the indoleacetic acid is free of embryotoxicity, safe and reliable. The application provides a new thought and means for early diagnosis and effective treatment of gestational diabetes mellitus, and has a wide application prospect.

The application provides a method for improving the bioavailability of puerarin, and belongs to the field of biological preparation, wherein puerarin and berberine are prepared into a puerarin-berberine compound, preferably hydrochloric acid berberine, and the molar ratio of the puerarin-berberine compound is 1:1, the method can improve the bioavailability of puerarin by tens of times, and further significantly improves the effect of puerarin on treating metabolic diseases caused by high-fat diet, improves physiological functions from multiple aspects, and has an excellent industrial application prospect.

The invention discloses lactobacillus plantarum ZYT028 and application thereof, the strain is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: M 20251257, and the lactobacillus plantarum ZYT028 has good acid cholate tolerance and intestinal colonization ability, can still keep high survival rate under the condition of pH 2.0, and can grow in an environment containing 1.0 g / L cholate. The ZYT028 strain can promote the generation of short-chain fatty acid and improve the imbalance of intestinal flora caused by high fat diet; in animal experiments, the content of serum total cholesterol and triglyceride can be remarkably reduced, excessive weight increase is inhibited, and good lipid-lowering and weight-regulating effects are shown. The strain disclosed by the invention can be widely applied to development of functional foods, health-care products, fermented dairy products and probiotic preparations, and is used for assisting in controlling body weight and improving blood lipid metabolism.

The invention relates to the technical field of microorganisms, in particular to a composite leavening agent with antioxidant activity and application. The compound fermentation agent is prepared from lactobacillus rhamnosus LGD-0817 and lactobacillus plantarum LEP-1208. The compound leavening agent is used for fermenting the traditional Chinese medicine composition, the antioxidant is added, the obtained traditional Chinese medicine fermentation composition contains probiotics, traditional Chinese medicine fermentation liquor and antioxidant substances, and the probiotics, the traditional Chinese medicine fermentation liquor and the antioxidant substances can effectively achieve a synergistic effect, so that free radicals in a body are efficiently removed, damage of oxidative stress to cells is reduced, and senescence is delayed. The traditional Chinese medicine fermented composition can effectively improve the intestinal flora structure, enhance the anti-oxidation defense capability of the body and inhibit inflammatory response through multiple ways, and shows a good comprehensive intervention effect in high-fat diet and D-galactose induced oxidative stress model mice; scientific basis is provided for applying the traditional Chinese medicine composition to products for delaying senescence and resisting oxidation, and the traditional Chinese medicine composition has clinical practical value.

The invention discloses goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder and application of the goose plasma protein source oligopeptide, and relates to the technical field of biology. The goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder is obtained through screening, and the amino acid sequence is GDWIVK. Animal experiments prove that the goose plasma protein source oligopeptide can effectively reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and liver affected by high fat diet, increase the content of high-density lipoprotein cholesterol, reduce liver lipid deposition and improve pathological injury of the liver. Meanwhile, the structure and diversity of intestinal flora can be adjusted, the abundance of beneficial bacteria and the content of short-chain fatty acid in excrement are increased, the reaction of colitis is relieved, and the synergistic adjustment effect is achieved through an intestinal tract-liver axis.

The invention discloses a novel intestinal probiotic butyric acid monad and application thereof, the novel intestinal probiotic butyric acid monad is preserved in Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC No.67648. A mouse model proves that the butyric acid monad can promote synthesis of intestinal TMP (Trimethoprim) by remodeling intestinal steady state, and then the TMP is converted into thiamine. Through intestinal liver circulation, thiamine accumulates in the liver and is further converted into TPP. The process promotes the degradation of BCAs, further regulates the lipid metabolism of the liver, and obviously alleviates the progress of metabolic dysfunction related fatty liver diseases induced by high fat diet.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The application discloses a plant lactobacillus gasseri strain capable of transforming ginsenoside and cassia glycoside, and application of the strain in lipid reduction and alleviation of fatty liver, and belongs to the fields of microbial technology, medicine and functional food. The core feature of the strain is that the strain can not only transform ginsenoside Rb1 into ginsenoside Rd with higher activity, but also transform cassia glycoside into cassia glycoside base, thereby improving the efficacy. The animal experiment proves that the strain and the corresponding substrate are combined to play a better role in lipid reduction and liver protection: the serum total cholesterol and triglyceride levels of high-fat diet mice can be effectively reduced, and the liver weight, liver lipid deposition and liver tissue fatty degeneration can be reduced and improved. The strain provides a new core strain and technical scheme for developing microecological preparations for preventing and / or assisting in treating hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases.

The present invention relates to a composition for the prevention or treatment of non-alcoholic fatty liver disease and a screening method for a non-alcoholic fatty liver disease treatment. More specifically, it was confirmed that FPR2 is expressed in the livers of female mice, whereas its expression is suppressed in the livers of male mice; it was confirmed that nodular and inflammatory responses increase in the livers of male mice fed a high-fat diet in which FPR2 expression is suppressed; and it was confirmed that liver fibrosis and inflammation increase in the livers of female mice fed a high-fat diet in which FPR2 expression is deficient. Accordingly, the FPR2 or an agent thereof may be provided as a composition for the prevention or treatment of non-alcoholic fatty liver disease.

The invention belongs to the technical field of biological medicines, and particularly relates to application of naringin in preparation of a medicine for preventing and / or treating ejection fraction retention type heart failure (HFpEF). A double-strike HFpEF mouse model induced by HFD (High Fat Diet) combined with L-NAME (N omega-nitro-L-arginine methyl ester) is constructed to prove that the naringin can obviously improve metabolic disorder, cardiovascular dysfunction and inflammatory injury of the HFpEF mouse and relieve myocardial hypertrophy and myocardial fibrosis of the mouse; therefore, the effect of preventing and / or treating the ejection fraction retention type heart failure can be achieved, and the naringin can be used as an active ingredient for preparing the medicine for preventing and / or treating the ejection fraction retention type heart failure.

The invention provides application of herpetonol in preparation of a medicine for treating or / and preventing fatty liver diseases. According to the invention, through a mouse model established by high fat diet (HFD) and a cell model induced by free fatty acid (FFA), the influence of herpetolol (HPO) on metabolic dysfunction related fatty liver disease (MASLD) is researched. In addition, through a drug affinity reaction target spot stability experiment (DARTS) and a cell thermal displacement experiment (CETSA), a key target spot of the action of the HPO and an action mechanism of the HPO are identified. Research finds that in an MASLD mouse model, the treatment of the hernol (HPO) significantly alleviates the lipid accumulation and inflammatory infiltration of the liver, and reveals that the hernol directly targets an adiponectin receptor 1 (ADIPOR1), up-regulates the expression of the ADIPOR1, activates an adenylate activated protein kinase (AMPK) pathway and further inhibits the nucleation regulation of sterol regulatory element binding protein 1c (SREBP-1c), thereby providing a potential direction for the treatment strategy of the MASLD.

The invention provides modified spirulina polysaccharide with an effect of regulating intestinal steady state and application of the modified spirulina polysaccharide, and belongs to the technical field of biological medicines. The preparation method of the modified spirulina polysaccharide comprises the following steps: mixing spirulina polysaccharide with a hydrochloric acid solution to prepare a polysaccharide solution, then adding sodium selenite and vitamin C, carrying out microwave treatment, and carrying out alcohol precipitation, precipitate collection and drying to obtain the modified spirulina polysaccharide. The modified spirulina polysaccharide disclosed by the invention has a remarkable effect of regulating the steady state of the intestinal tract, and has an outstanding effect on intestinal tract ecological disorder induced by high-fat diet. The modified spirulina polysaccharide and the coptis chinensis extract are combined to prepare products for preventing and treating intestinal ecological imbalance caused by oral administration of antibiotics. The coptis chinensis extract prepared by the invention can inhibit gram-positive pathogenic bacteria and protect gram-negative beneficial bacteria, and cooperates with the modified spirulina polysaccharide to promote colonization of intestinal probiotics (bifidobacterium and lactobacillus) and improve intestinal ecological imbalance.